Apolipoprotein C-III inhibitors - Pipeline Insight, 2022

January 2022 | 60 pages | ID: A22C9A232D6CEN
DelveInsight

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight’s, “Apolipoprotein C-III inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Apolipoprotein C-III inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Apolipoprotein C-III inhibitors Understanding

Apolipoprotein C-III inhibitors: Overview

Apolipoprotein C-III (APOC3) is a key regulator of lipoprotein metabolism and plays a pivotal role in regulating plasma triglyceride levels. It is synthesized principally in the liver and is a component of triglyceride-rich lipoproteins. It is known to inhibit lipoprotein lipase–mediated hydrolysis of triglyceride-rich lipoproteins and to adversely affect receptor-mediated hepatic uptake of remnants of triglyceride-rich lipoproteins.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Apolipoprotein C-III inhibitors R&D. The therapies under development are focused on novel approaches for Apolipoprotein C-III inhibitors.

Apolipoprotein C-III inhibitors Emerging Drugs Chapters

This segment of the Apolipoprotein C-III inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Apolipoprotein C-III inhibitors Emerging Drugs

• IONIS-APOCIII-LRx: Ionis Pharmaceuticals

IONIS-APOCIII-LRx, formerly known as AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III, for patients who are at risk of disease due to elevated triglyceride levels. ApoC-III is a protein produced in the liver that regulates triglyceride metabolism in the blood. People with severely elevated triglycerides, such as people with familial chylomicronemia syndrome (FCS), are at high risk for acute pancreatitis and other serious conditions. ApoC-III is also the target of WAYLIVRA, the first approved medicine for patients with FCS.

• ARO-APOC3: Arrowhead Pharmaceuticals,

ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.

Further product details are provided in the report……..

Apolipoprotein C-III inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Apolipoprotein C-III inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Apolipoprotein C-III inhibitors

There are approx. 3+ key companies which are developing the Apolipoprotein C-III inhibitors. The companies which have their Apolipoprotein C-III inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Apolipoprotein C-III inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Apolipoprotein C-III inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Apolipoprotein C-III inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Apolipoprotein C-III inhibitors drugs.

Apolipoprotein C-III inhibitors Report Insights

• Apolipoprotein C-III inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Apolipoprotein C-III inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Apolipoprotein C-III inhibitors drugs?
• How many Apolipoprotein C-III inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Apolipoprotein C-III inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Apolipoprotein C-III inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Apolipoprotein C-III inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ionis Pharmaceuticals
• Arrowhead Pharmaceuticals
• argenx
• Korea United Pharm I

Key Products

• IONIS-APOCIII-LRx
• Volanesorsen
• ARO APOC3
• ARGX 116
• UI 014

Contents

Introduction
Executive Summary
Apolipoprotein C-III inhibitors: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Apolipoprotein C-III inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
  Comparative Analysis
IONIS-APOCIII-LRx: Ionis Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
ARO APOC3: Arrowhead Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
ARGX 116: argenx
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Apolipoprotein C-III inhibitors Key Companies
Apolipoprotein C-III inhibitors Key Products
Apolipoprotein C-III inhibitors- Unmet Needs
Apolipoprotein C-III inhibitors- Market Drivers and Barriers
Apolipoprotein C-III inhibitors- Future Perspectives and Conclusion
Apolipoprotein C-III inhibitors Analyst Views
Apolipoprotein C-III inhibitors Key Companies
Appendix